News Channels

23 Jul 2019 Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
23 Jul 2019 Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa
23 Jul 2019 FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
23 Jul 2019 Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
23 Jul 2019 Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors
23 Jul 2019 DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
23 Jul 2019 Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
23 Jul 2019 Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis
23 Jul 2019 IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
23 Jul 2019 Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV
23 Jul 2019 ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
23 Jul 2019 ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
22 Jul 2019 Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
22 Jul 2019 Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
22 Jul 2019 Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
21 Jul 2019 Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
21 Jul 2019 PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke
21 Jul 2019 Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
21 Jul 2019 FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
21 Jul 2019 Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX® (daratumumab)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up